Check out your Company Bowl for anonymous work chats.
Choosing a human reference #genome for mapping and variant calling can be challenging. #DRAGEN developed a graph-based genome to improve mapping accuracy, read our latest research article to learn more. #GIAB
A multi-cancer early detection liquid biopsy for pet dogs is here, thanks to San Diego-based PetDx. The molecular diagnostics company was founded by an Illumina alumnus, Daniel S. Grosu with the help of his pup Nala. #IlluminaAlumniNetwork #Genomics
Congratulations to our very own Francis deSouza and Sam Samad for being named to the San Diego Business Journal SD500 list. These two exemplify strong leadership skills, embrace diversity, inclusion and equity and are significantly involved in the community. Congratulations to all the winners!
“I joined Illumina because of my passion in applying science to solve challenging problems which can positively impact society. I decided to stay because I found an inclusive and diverse community of top scientists that motivate and support me to grow as a mentor, researcher, and scientist.” --Maria Proetto, Senior Scientist in the Consumables & Assay Development Department. Explore career opportunities at Illumina. #Careers #Genomics
Career growth and development, culture, a sense of belonging, and innovation are just a few of the things we’re most proud of for landing us on the BioSpace Best Places to Work list. #Genomics
Pharmacogenomic testing helps healthcare providers remove the trial and error from treating mental illness. Hear from board-certified psychiatrist Dr. Julio Monterrey about how PGx enables him to better serve patients. #Pharmacogenomics #MentalIllnessAwareness
Pushing the boundaries of #genomics to unlock human health is a critical focus of Amanda Cashin, PhD. Hear from Dr. Cashin about how and why Illumina For Startups has helped launch 61 companies in the last 7 years.
We're excited to be named to the Dow Jones Sustainability World Index (DJSI) for the third year in a row! We are working to embed ESG in all we do. This recognition further reflects our commitment to continuously improving and growing our #CSR program to build a more #sustainable and equitable future for all.
Today the New England Journal of Medicine published a world-first scientific study on how whole-genome sequencing (WGS) can uncover new diagnoses for people with previously undetectable rare diseases. The study, for which Illumina was the sequencing partner, was led by Genomics England and Queen Mary University of London and undertaken in partnership with the NIHR (National Institute for Health Research) BioResource. The pilot study shows that WGS can effectively secure a rare disease diagnosis for patients, save the NHS vital resources, and pave the way for other interventions. For 25% of study participants, their diagnosis meant they were able to receive more focused clinical care, including further family screening, dietary change, provision of vitamins and / or minerals and other therapies. #Genomes100k
Congratulations to our regional marketing team for their Multiomics campaign award from MarCom Awards! The campaign was gorgeous, but the real winners are scientists and researchers who can now better connect variants to function and power even #MORE discoveries!
